Evidence map›Paper›PMID 37046680›Full record

ReviewCancers2023

Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech.

Eric Wegener, Justin Samuels, Mark Sidhom, Yuvnik Trada, Swetha Sridharan, Samuel Dickson, Nicholas McLeod, Jarad M Martin

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Eric WegenerSchool of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0003-0795-0984
Justin SamuelsDepartment of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.
Mark SidhomDepartment of Radiation Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Yuvnik TradaDepartment of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.
Swetha SridharanDepartment of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.
Samuel DicksonDepartment of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.
Nicholas McLeodDepartment of Urology, John Hunter Hospital, Newcastle, NSW 2305, Australia.
Jarad M MartinSchool of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.
Calvary Mater Newcastle Hospital · AUAustralian and New Zealand Intensive Care Society · AUJohn Hunter Hospital · AULiverpool Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is the most common malignancy in men. Internal radiotherapy (brachytherapy) has been used to treat PC successfully for over a century. In particular, there is level-one evidence of the benefits of using brachytherapy to escalate the dose of radiotherapy compared with standard external beam radiotherapy approaches. However, the use of PC brachytherapy is declining, despite strong evidence for its improved cancer outcomes. A method using external beam radiotherapy known as virtual high-dose-rate brachytherapy boost (vHDRB) aims to noninvasively mimic a brachytherapy boost radiation dose plan. In this review, we consider the evidence supporting brachytherapy boosts for PC and the continuing evolution of vHDRB approaches, culminating in the current generation of clinical trials, which will help define the role of this emerging modality.

Indexed as

boostbrachytherapyprostate cancerreviewstereotactic body radiotherapy (SBRT)

Identifiers

PMID37046680
PMCPMC10093761
OpenAlexW4361288710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.